- Home
- YI vs IMAB Comparison
YI vs IMAB Comparison
Compare YI & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- IMAB
- Stock Information
- Founded
- YI 2010
- IMAB 2014
- Country
- YI China
- IMAB United States
- Employees
- YI N/A
- IMAB N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- IMAB Health Care
- Exchange
- YI Nasdaq
- IMAB Nasdaq
- Market Cap
- YI 70.0M
- IMAB 73.9M
- IPO Year
- YI N/A
- IMAB 2020
- Fundamental
- Price
- YI $8.00
- IMAB $2.50
- Analyst Decision
- YI
- IMAB Strong Buy
- Analyst Count
- YI 0
- IMAB 2
- Target Price
- YI N/A
- IMAB $5.50
- AVG Volume (30 Days)
- YI 11.5K
- IMAB 1.0M
- Earning Date
- YI 06-19-2025
- IMAB 05-15-2025
- Dividend Yield
- YI N/A
- IMAB N/A
- EPS Growth
- YI N/A
- IMAB N/A
- EPS
- YI N/A
- IMAB N/A
- Revenue
- YI $1,984,717,013.00
- IMAB N/A
- Revenue This Year
- YI N/A
- IMAB N/A
- Revenue Next Year
- YI N/A
- IMAB N/A
- P/E Ratio
- YI N/A
- IMAB N/A
- Revenue Growth
- YI N/A
- IMAB N/A
- 52 Week Low
- YI $4.15
- IMAB $0.60
- 52 Week High
- YI $12.90
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- YI 49.11
- IMAB 67.42
- Support Level
- YI $7.40
- IMAB $2.29
- Resistance Level
- YI $8.69
- IMAB $2.69
- Average True Range (ATR)
- YI 0.41
- IMAB 0.35
- MACD
- YI -0.02
- IMAB 0.00
- Stochastic Oscillator
- YI 46.51
- IMAB 64.53
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).